Complement-Mediated Selective Tumor Cell Lysis Enabled by Bi-Functional RNA Aptamers.

Area of Science:

• Immunology
• Biotechnology
• Molecular Biology

Background:

• Cancer cells evade immune detection as they originate from host cells.
• Synthetic targeting strategies are needed to direct immune responses against malignant cells.

Purpose of the Study:

• To develop aptamer-derived molecular adaptors for invoking synthetic immune responses against cancer.
• To create multi-valent aptamers that bridge cancer cell surface targets and complement proteins.

Main Methods:

• Designed and constructed bi-functional aptamers linking epidermal growth factor receptor (EGFR) and complement component 3b (C3b)/iC3b.
• Utilized cell-based assays with breast cancer cell lines (MDA-MB-231, BT-20) and human or mouse serum.

Main Results:

• Demonstrated aptamer-mediated binding to both cancer cell surface targets and complement proteins.
• Successfully induced lysis of MDA-MB-231 and BT-20 breast cancer cells via complement activation.

Conclusions:

• Multi-valent aptamers can effectively earmark cancer cells for immune destruction by engaging the complement system.
• This aptamer-based approach offers a promising strategy for synthetic immune targeting in cancer therapy.